CABA

Cabaletta Bio, Inc.

23.96 USD
-0.01 (-0.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cabaletta Bio, Inc. stock is up 8.76% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 March’s closed higher than February. In the last 8 Unusual Options Trades, there were 4 PUTs, 4 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
09 Jan 15:48 16 Aug, 2024 20.00 PUT 59 0
10 Jan 14:30 16 Feb, 2024 10.00 CALL 22 27
19 Jan 18:45 20 Dec, 2024 12.50 CALL 40 0
02 Feb 20:47 16 Aug, 2024 17.50 PUT 2500 0
08 Feb 16:15 15 Mar, 2024 22.50 PUT 155 1023
15 Feb 16:21 15 Mar, 2024 30.00 CALL 700 1546
16 Feb 15:39 16 Feb, 2024 12.50 CALL 25 79
16 Feb 20:04 16 Aug, 2024 17.50 PUT 2500 2500

About Cabaletta Bio, Inc.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.